Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

Massimo, Breccia; Laura, Cannella; Stefanizzi, Caterina; Michelina, Santopietro; Rosa De Cuia,; Daniela, Diverio; Alimena, Giuliana

doi:10.1016/j.leukres.2008.10.024

CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400 mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late CP, which were switched to imatinib while in CCR after interferon alpha (IFN alpha) and reached complete and stable molecular remission with intermittent drug administration at 400 mg/every 20 days/month. (C) 2008 Elsevier Ltd. All rights reserved.

Scheda prodotto non validato

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Titolo:	Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
Autori:	Massimo Breccia Laura Cannella STEFANIZZI, CATERINA Michelina Santopietro Rosa De Cuia Daniela Diverio ALIMENA, Giuliana mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2009
Rivista:	LEUKEMIA RESEARCH
Abstract:	Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400 mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late CP, which were switched to imatinib while in CCR after interferon alpha (IFN alpha) and reached complete and stable molecular remission with intermittent drug administration at 400 mg/every 20 days/month. (C) 2008 Elsevier Ltd. All rights reserved.
Handle:	http://hdl.handle.net/11573/30630
Appare nella tipologia:	01a Articolo in rivista

File allegati a questo prodotto

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11573/30630

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.